Treatment Progress of Paroxysmal Sympathetic Hyperactivity after Acquired Brain Injury.
Paroxysmal sympathetic hyperactivity (PSH) is a common complication of various acquired brain injuries such as traumatic brain injury, subarachnoid hemorrhage, anoxic brain injury, intracerebral hemorrhage, and others. It is manifested by tachycardia, hypertension, tachypnea, diaphoresis, and dystonic posturing. The development of PSH can prolong hospitalization and lead to secondary brain injury and even death. Despite the awareness of the serious clinical impact, there is no consensus on diagnostic criteria. Thus, misdiagnosis and delayed recognition is very common. Most of the current treatment programs come from case reports and small case series; there are very few large-scale randomized controlled trials. Generally accepted medications are opioids, β-blockers and gabapentin (usually used in combination). However, the efficacy of these drugs has not been systematically assessed. The purpose of this review is to determine the treatment strategies and drugs commonly used for PSH at the overall level.
Ying
Y
Feng
Xiang
X
Zheng
Zhicheng
Z
Fang
D001930:Brain Injuries / Q000150:complications*; D006801:Humans; D054969:Primary Dysautonomias / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology